Clinicopathologic features and outcome of cervical cancer: implications for treatment

Clinicopathologic features and outcome of cervical cancer: implications for treatment
复制标题

DOI:
10.26355/eurrev_202101_24631
复制
发表时间:
2021-01-01
影响因子:
3.3
通讯作者:
Zhu, X.
Zhu, X.
中科院分区:
医学4区
文献类型:
--
作者:
Liang, B-Q;Zhou, S-G;Zhu, X.

文献摘要

被引文献

相似文献

目的:我们使用的SEER数据库的回归分析,建立一个新的诺模图预测宫颈癌患者的预后和指导treatment.MATERIALS和METHODS:我们分为训练队列和验证队列的数据。采用单因素和多因素考克斯风险回归分析确定独立的预后因素并建立Nomogram模型。采用验证队列进行外部验证,用C指数和AUC评价准确性。终于来了结果:共纳入5691例宫颈鳞状细胞癌患者。从培训队列中获得的数据是宫颈癌AJCC分期(p = 0.039)、RX汇总-手术原发部位(p = 0.012)、放疗(p = 0.031)、化疗(p = 0.013)、肿瘤大小(p = 0.009)、人种(p = 0.039)的独立风险因素。一年。宫颈癌患者3年、5年总生存率分别为77.2%、47.8%、35.2%。结论:诺模图模型能更好地筛选出适合不同分期患者的综合治疗方案。并且对提高宫颈癌患者的生存率、降低复发率有很大帮助。
OBJECTIVE: We used a regression analysis of the SEER database to establish a new Nomogram for predicting prognosis of cervical cancer patients and guiding the treatment.MATERIALS AND METHODS: We divided the data into the training cohort and the verification cohort. Univariate and multivariate Cox risk regression analysis was used to identify independent prognostic factors and establish a Nomogram model. The verification cohort was used for external verification, and the accuracy was evaluated with C-index and AUC. Finally. Nomogram was used to establish 1-year, 3-year and 5-year survival curves of cervical cancer patients.RESULTS: In this study, 5691 patients with cervical squamous cell carcinoma were included. Data obtained from the training cohort were independent risk factors of cervical cancer AJCC stage (p = 0.039), RX Summ - Surgery Primary Site (p = 0.012), radiation (p = 0.031), chemotherapy (p = 0.013), tumor size (p = 0.009), race (p = 0.039). The 1-year. 3-year, and 5-year overall survival rates for cervical cancer patients were 77.2%, 47.8%, and 35.2%, respectively.CONCLUSIONS: The Nomogram model can better screen out more reasonable comprehensive treatments for patients at different stages. And it is of great help to improve the survival rate and reduce the recurrence rate of cervical cancer patients.